BASF’s Abrupt Withdrawal From the Evonik Take‑over Leaves the Market in Shock

BASF SE’s sudden retreat from an $12 billion bid for Evonik Industries has rattled investors and sent the German chemical group’s shares tumbling past the 200‑day moving average. The move, announced on Tuesday after weeks of speculation, signals a strategic recalibration that could reshape the competitive landscape of Europe’s chemical sector.

The Bid and Its Rejection

The proposed purchase had been framed as a strategic step to consolidate BASF’s position across its six core segments—chemicals, plastics, performance products, functional solutions, agricultural solutions, and oil and gas. Yet Evonik’s board, backed by its largest shareholder, the RAG‑Stiftung, rejected the offer, citing insufficient valuation and the lack of a comprehensive dialogue between the parties. The rejection forced BASF to abandon the deal, a decision that was met with sharp criticism from the trade union IG BCE and other stakeholders who argued that BASF’s abrupt withdrawal was poorly timed and poorly communicated.

Market Reaction

BASF’s share price, which closed at €49.36 on 19 November, fell 1 % the next day and breached the critical 200‑day technical level. The 200‑day line, a key indicator for long‑term investors, was crossed at a price that sits well below the 52‑week high of €56.56 and within a range that has already tested the company’s resilience following the global downturn in industrial demand. Analysts warn that the price decline could trigger stop‑loss orders and further erode confidence in BASF’s strategic vision.

RAG‑Stiftung’s Public Statement

The RAG‑Stiftung, Evonik’s largest shareholder, released a statement expressing disappointment in the “inadequate exchange” between the chemical giants. The foundation’s spokesperson emphasized the need for deeper dialogue before any future acquisition talks, a stance that echoes the sentiments of the IG BCE and underscores the increasing pressure on BASF to adopt a more transparent approach to corporate governance.

Strategic Implications

BASF’s decision to walk away from the Evonik bid raises questions about the company’s long‑term growth strategy. While the acquisition was intended to broaden BASF’s portfolio and deliver synergies across overlapping product lines, the withdrawal may signal a shift toward organic growth and a refocus on core competencies. However, the move also exposes BASF to renewed competitive threats from rivals such as Bayer, Dow, and DuPont, who continue to expand their footholds in high‑margin specialty chemicals.

Investor Outlook

The market’s reaction—evident in the share price plunge and the breach of a critical technical barrier—suggests that investors are demanding more decisive leadership from BASF’s board. The company’s price‑to‑earnings ratio of 21.02, while still within an acceptable range for the sector, will likely face scrutiny as the firm seeks to restore investor confidence and demonstrate a clear path to sustainable profitability.

In the days ahead, all eyes will be on BASF’s next strategic announcement. Whether the company chooses to re‑engage with Evonik, pivot toward new markets, or reinforce its existing segments, the outcome will shape not only BASF’s future but also the broader trajectory of the global chemical industry.